Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + candesartan + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of bevacizumab (a monoclonal antibody targeting VEGF-A), candesartan (an angiotensin II receptor blocker), and pemetrexed (an antifolate chemotherapy agent). This combination is designed to attack multiple synthetic lethal vulnerabilities in cancer treatment.
- Other names
- PBC
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + candesartan + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + candesartan + pemetrexed.